Chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MeS) are common chronic disease with increasing prevalence. One of the main causes of death with COPD has been cardiovascular disease. This study was undertaken to evaluate the clinical characteristics and the risk factors for MeS in male patients with COPD.
The 1,879 male subjects (aged 40–70 years) were enrolled in this survey participated in the Korean Rural Genomic Cohort study. They were devided into four groups depending on the presence of MeS and COPD (group1 = normal control without MeS, group2 = normal control with MeS, group3 = COPD without MeS, group4 = COPD with MeS). COPD was defined as a FEV1/FVC ratio < 0.7 and MeS was defined according to the criteria of National Cholesterol Education Programme's Adult Treatment Panel III. Spirometry was performed according to American Thoracic Society recommendations. Body composition analysis was measured by bioelectrical impedance. C-reactive protein (CRP), leptin and adiponectin were measured.
Among the COPD patients, body mass index (BMI), fat free mass index (FFMI), visceral fat mass index (VFMI) and waist circumference (WC) were more increased in group4 than group3 significantly (p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively). As inflammatory markers, the levels of leptin were higher in group4 than group3 (p < 0.001) and those of adiponectin were lower in group4 than group3, significantly (p < 0.001). The ratio of leptin/adiponectin was significantly higher in group4 than group3 (p < 0.001). Adjusted odds ratio of leptin and leptin/adiponectin ratio for MeS in COPD patients were 1.16 (95%CI 1.01–1.32) and 1.98 (95%CI 1.11–3.53) respectively.
The levels of leptin and leptin/adiponectin ratio may be useful markers for prediction of MeS in male COPD patients.
Measurement of the level of leptin and adiponectin may be useful to detect the risk group for MeS in COPD patients. It would be important for reducing the morbidity and mortality due to cardiovascular diseases in COPD patients.
Sang-Ha Kim, No Financial Disclosure Information; No Product/Research Disclosure Information